查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1575499

酶抑制劑市場：按產品類型、應用、最終用戶、抑制機制、治療領域、分子類型、酶目標 - 2025-2030 年全球預測

Enzyme Inhibitor Market by Product Type, Application, End User, Inhibition Mechanism, Therapeutic Area, Molecule Type, Enzyme Target - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年酵素抑制劑市值為21.4億美元，預計到2024年將達到22.5億美元，複合年成長率為7.07%，到2030年將達到34.5億美元。

酵素抑制劑是與酵素結合併降低其活性的分子，在多種藥物應用中發揮重要作用，包括治療癌症和心血管疾病等疾病。對酵素抑制劑的需求源自於它們調節生化途徑並透過控制酵素活性產生治療效果的能力。酵素抑制劑廣泛應用於藥物開發、農業和生化研究，主要最終用途領域為製藥、農業和生物技術。酶抑制劑市場的成長主要是由研發活動的增加、需要先進治療的慢性疾病數量的增加以及生物技術行業的大量投資所推動的。關鍵影響因素包括精準醫學的進步、使用酵素抑制劑進行客製化治療的基因組研究以及增強藥物發現過程的高通量篩檢和生物資訊學等強大的技術發展。潛在的商機在於對標靶治療不斷成長的需求、擴大新興國家開拓的市場以及擴大農業和工業酶抑制劑等非傳統應用的應用。然而，它們面臨著限制和挑戰，例如高昂的研發成本、嚴格的法律規範、潛在的副作用導致毒性以及來自替代療法的競爭。業務成長可能會透過圍繞具有更高選擇性、效力和安全性的新型酶抑制劑製劑的創新，以及在藥物發現中使用人工智慧和機器學習進行預測建模來實現。該市場是動態的，其特點是主要聯盟和合併以促進研究和開發，以及不斷努力解決未滿足的醫療需求。儘管面臨全球經濟情勢波動和關鍵藥物專利到期的挑戰，但基礎設施和醫療改革快速進展的地區為業務擴張和戰略投資提供了一個有希望的途徑。因此，對新興生物技術和個人化醫療的關注可以支持該領域的指數成長和永續性。

主要市場統計
基準年[2023] 21.4億美元
預測年份 [2024] 22.5億美元
預測年份 [2030] 34.5億美元
複合年成長率（%） 7.07%

市場動態：快速發展的酶抑制劑市場的關鍵市場洞察

供需的動態交互作用正在改變酵素抑制劑市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 對治療慢性病的標靶治療的需求不斷成長
    • 生物技術的快速進步導致新型酵素抑制劑的開發
    • 酵素相關疾病盛行率上升促使需要有效的抑制劑
    • 產業巨頭加大醫藥研發投入
  • 市場限制因素
    • 製藥公司正在將重點轉向生技藥品，而不是傳統的酵素抑制劑。
    • 替代療法的激烈競爭限制了酵素抑制劑市場的成長
  • 市場機會
    • 利用酵素抑制劑實現個人化醫療保健中的精準醫療方法
    • 將酵素抑制劑納入聯合治療以提高多重抗藥性癌症的治療效果
    • 探索酶抑制劑在農業中的應用，以改善作物保護和產量永續性
  • 市場挑戰
    • 管理供應鏈中斷並確保酵素抑制劑生產的品質穩定
    • 解決酶抑制劑領域的擴充性問題以及特定治療應用的可自訂性

波特五力：駕馭酵素抑制劑市場的策略工具

波特的五力框架是了解酵素抑制劑市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解酵素抑制劑市場的外部影響

外部宏觀環境因素在塑造酶抑制劑市場的表現動態中起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助企業預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解酵素抑制劑市場的競爭狀況

對酶抑制劑市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位基質酶抑制劑市場供應商績效評估

FPNV定位矩陣是評估酵素抑制劑市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，以規劃酶抑制劑市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對酶抑制劑市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 對治療慢性疾病的標靶治療的需求增加
      • 透過生物技術的快速進步開發新的酶抑制劑
      • 酵素相關疾病盛行率的上升增加了對有效抑制劑的需求
      • 主要產業參與者加大醫藥研發投入
    • 抑制因素
      • 製藥公司正在將重點轉向生技藥品而不是傳統的酵素抑制劑
      • 替代療法的激烈競爭限制了酵素抑制劑市場的成長
    • 機會
      • 在個人化醫療解決方案中利用酵素抑制劑進行精準醫學方法
      • 將酵素抑制劑納入聯合治療以改善多重抗藥性癌症的治療結果
      • 探索酵素抑制劑在農業中的應用，以改善作物保護和產量永續性
    • 任務
      • 管理供應鏈中斷並確保酵素抑制劑生產品質穩定
      • 解決酶抑制劑領域特定治療應用的可擴展性問題和可自訂性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章酶抑制劑市場：依產品類型

  • 競爭性抑制劑
    • 不可逆抑制劑
    • 可逆抑制劑
  • 非競爭性抑制劑
    • 變構抑制劑
    • 混合抑制劑
  • 非競爭性抑制劑

第7章酶抑制劑市場：依應用分類

  • 農業
  • 生物催化劑
  • 藥品
  • 研究和生物技術

第8章酶抑制劑市場：依最終用戶分類

  • 學術研究所
  • 合約調查機構
  • 醫院/診所
  • 製藥公司

第9章依抑制機制分類的酵素抑制劑市場

  • 共用抑制劑
  • 非共用抑制劑

第10章依治療領域分類的酵素抑制劑市場

  • 心臟病學
    • 抗凝血物
    • 抗高血壓藥
  • 感染疾病
    • 抗菌劑
    • 抗真菌藥物
    • 抗病毒藥物
  • 神經病學
    • 抗憂鬱症
    • 抗癲癇藥
  • 腫瘤學
    • 化療
    • 標靶治療

第11章按分子類型分類的酵素抑制劑市場

  • 聚合物抑制劑
  • 小分子抑制劑

第12章酶抑制劑市場酶目標

  • 激酶
  • 磷酸酶
  • 聚合酵素
  • 蛋白酶

第13章美洲酶抑制劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第14章亞太地區酵素抑制劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第15章 歐洲、中東和非洲酵素抑制劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第16章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C0579

The Enzyme Inhibitor Market was valued at USD 2.14 billion in 2023, expected to reach USD 2.25 billion in 2024, and is projected to grow at a CAGR of 7.07%, to USD 3.45 billion by 2030.

Enzyme inhibitors are molecules that bind to enzymes and decrease their activity, serving critical roles in various pharmaceutical applications, including treating diseases such as cancer, cardiovascular diseases, and more. The necessity of enzyme inhibitors arises from their ability to regulate the biochemical pathways by controlling the activity of enzymes, providing therapeutic benefits. They are widely applied in drug development, agriculture, and biochemical research, with major end-use sectors being pharmaceuticals, agriculture, and biotechnology. The market growth for enzyme inhibitors is primarily driven by increasing R&D activities, the rise in chronic diseases necessitating advanced treatments, and substantial investments in biotechnology industries. Key influencing factors include advancements in precision medicine, genomic studies empowering tailored therapies using enzyme inhibitors, and robust technological developments like high-throughput screening and bioinformatics enhancing drug discovery processes. Potential opportunities prevail in the growing demand for targeted therapies, substantial untapped markets in emerging economies, and expanding applications for non-traditional uses such as agriculture and industrial enzyme inhibitors. However, the market faces limitations and challenges such as high R&D costs, stringent regulatory frameworks, potential side effects leading to toxicity, and competition from alternative therapies. Business growth could be capitalized by innovations concerning novel enzyme inhibitor formulations with higher selectivity, potency, and safety profiles, alongside leveraging AI and machine learning for predictive modeling in drug discovery. The market is dynamic, characterized by significant collaborations and mergers to foster R&D, with a continuous endeavor to address unmet medical needs. Fluctuating global economic conditions and patent expiration of key drugs can pose challenges, yet regions with burgeoning infrastructure and healthcare reforms indicate promising avenues for expansion and strategic investments. Thus, focusing on emerging biotechnologies and personalized medicine could underpin exponential growth and sustainability in this sector.

KEY MARKET STATISTICS
Base Year [2023] USD 2.14 billion
Estimated Year [2024] USD 2.25 billion
Forecast Year [2030] USD 3.45 billion
CAGR (%) 7.07%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Enzyme Inhibitor Market

The Enzyme Inhibitor Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing demand for targeted therapies in the treatment of chronic diseases
    • Rapid advancements in biotechnology leading to novel enzyme inhibitors development
    • Rising prevalence of enzyme-related disorders driving the need for effective inhibitors
    • Growing investments in pharmaceutical research and development by major industry players
  • Market Restraints
    • Pharmaceutical companies shifting focus towards biologics over traditional enzyme inhibitors
    • Stiff competition from alternative treatments restraining the growth of enzyme inhibitor market
  • Market Opportunities
    • Leveraging enzyme inhibitors for precision medicine approaches in personalized healthcare solutions
    • Integration of enzyme inhibitors in combination therapies to enhance treatment outcomes for multi-drug resistance cancers
    • Exploration of enzyme inhibitors in agricultural applications to improve crop protection and yield sustainability
  • Market Challenges
    • Managing supply chain disruptions and ensuring consistent quality in enzyme inhibitor production
    • Addressing scalability issues and customizability for specific therapeutic applications in the enzyme inhibitor sector

Porter's Five Forces: A Strategic Tool for Navigating the Enzyme Inhibitor Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Enzyme Inhibitor Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Enzyme Inhibitor Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Enzyme Inhibitor Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Enzyme Inhibitor Market

A detailed market share analysis in the Enzyme Inhibitor Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Enzyme Inhibitor Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Enzyme Inhibitor Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Enzyme Inhibitor Market

A strategic analysis of the Enzyme Inhibitor Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Enzyme Inhibitor Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Enzyme Inhibitor Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Competitive Inhibitors, Non-Competitive Inhibitors, and Uncompetitive Inhibitors. The Competitive Inhibitors is further studied across Irreversible Inhibitors and Reversible Inhibitors. The Non-Competitive Inhibitors is further studied across Allosteric Inhibitors and Mixed Inhibitors.
  • Based on Application, market is studied across Agriculture, Biocatalysts, Pharmaceuticals, and Research & Biotechnology.
  • Based on End User, market is studied across Academic & Research Institutes, Contract Research Organizations, Hospitals & Clinics, and Pharmaceutical Companies.
  • Based on Inhibition Mechanism, market is studied across Covalent Inhibitors and Non-Covalent Inhibitors.
  • Based on Therapeutic Area, market is studied across Cardiology, Infectious Diseases, Neurology, and Oncology. The Cardiology is further studied across Anti-Coagulants and Anti-Hypertensives. The Infectious Diseases is further studied across Antibacterials, Antifungals, and Antivirals. The Neurology is further studied across Anti-Depressants and Anti-Epileptics. The Oncology is further studied across Chemotherapy and Targeted Therapy.
  • Based on Molecule Type, market is studied across Large Molecule Inhibitors and Small Molecule Inhibitors.
  • Based on Enzyme Target, market is studied across Kinases, Phosphatases, Polymerases, and Proteases.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing demand for targeted therapies in the treatment of chronic diseases
      • 5.1.1.2. Rapid advancements in biotechnology leading to novel enzyme inhibitors development
      • 5.1.1.3. Rising prevalence of enzyme-related disorders driving the need for effective inhibitors
      • 5.1.1.4. Growing investments in pharmaceutical research and development by major industry players
    • 5.1.2. Restraints
      • 5.1.2.1. Pharmaceutical companies shifting focus towards biologics over traditional enzyme inhibitors
      • 5.1.2.2. Stiff competition from alternative treatments restraining the growth of enzyme inhibitor market
    • 5.1.3. Opportunities
      • 5.1.3.1. Leveraging enzyme inhibitors for precision medicine approaches in personalized healthcare solutions
      • 5.1.3.2. Integration of enzyme inhibitors in combination therapies to enhance treatment outcomes for multi-drug resistance cancers
      • 5.1.3.3. Exploration of enzyme inhibitors in agricultural applications to improve crop protection and yield sustainability
    • 5.1.4. Challenges
      • 5.1.4.1. Managing supply chain disruptions and ensuring consistent quality in enzyme inhibitor production
      • 5.1.4.2. Addressing scalability issues and customizability for specific therapeutic applications in the enzyme inhibitor sector
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Enzyme Inhibitor Market, by Product Type

  • 6.1. Introduction
  • 6.2. Competitive Inhibitors
    • 6.2.1. Irreversible Inhibitors
    • 6.2.2. Reversible Inhibitors
  • 6.3. Non-Competitive Inhibitors
    • 6.3.1. Allosteric Inhibitors
    • 6.3.2. Mixed Inhibitors
  • 6.4. Uncompetitive Inhibitors

7. Enzyme Inhibitor Market, by Application

  • 7.1. Introduction
  • 7.2. Agriculture
  • 7.3. Biocatalysts
  • 7.4. Pharmaceuticals
  • 7.5. Research & Biotechnology

8. Enzyme Inhibitor Market, by End User

  • 8.1. Introduction
  • 8.2. Academic & Research Institutes
  • 8.3. Contract Research Organizations
  • 8.4. Hospitals & Clinics
  • 8.5. Pharmaceutical Companies

9. Enzyme Inhibitor Market, by Inhibition Mechanism

  • 9.1. Introduction
  • 9.2. Covalent Inhibitors
  • 9.3. Non-Covalent Inhibitors

10. Enzyme Inhibitor Market, by Therapeutic Area

  • 10.1. Introduction
  • 10.2. Cardiology
    • 10.2.1. Anti-Coagulants
    • 10.2.2. Anti-Hypertensives
  • 10.3. Infectious Diseases
    • 10.3.1. Antibacterials
    • 10.3.2. Antifungals
    • 10.3.3. Antivirals
  • 10.4. Neurology
    • 10.4.1. Anti-Depressants
    • 10.4.2. Anti-Epileptics
  • 10.5. Oncology
    • 10.5.1. Chemotherapy
    • 10.5.2. Targeted Therapy

11. Enzyme Inhibitor Market, by Molecule Type

  • 11.1. Introduction
  • 11.2. Large Molecule Inhibitors
  • 11.3. Small Molecule Inhibitors

12. Enzyme Inhibitor Market, by Enzyme Target

  • 12.1. Introduction
  • 12.2. Kinases
  • 12.3. Phosphatases
  • 12.4. Polymerases
  • 12.5. Proteases

13. Americas Enzyme Inhibitor Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Enzyme Inhibitor Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Enzyme Inhibitor Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca PLC
  • 5. Bayer AG
  • 6. Biogen Inc.
  • 7. Boehringer Ingelheim GmbH
  • 8. Bristol-Myers Squibb Company
  • 9. Eli Lilly and Company
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline plc
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Novartis AG
  • 15. Novo Nordisk A/S
  • 16. Pfizer Inc.
  • 17. Regeneron Pharmaceuticals, Inc.
  • 18. Roche Holding AG
  • 19. Sanofi S.A.
  • 20. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. ENZYME INHIBITOR MARKET RESEARCH PROCESS
  • FIGURE 2. ENZYME INHIBITOR MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ENZYME INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. ENZYME INHIBITOR MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. ENZYME INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ENZYME INHIBITOR MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ENZYME INHIBITOR MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ENZYME INHIBITOR MARKET DYNAMICS
  • TABLE 7. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY IRREVERSIBLE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY REVERSIBLE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY MIXED INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY UNCOMPETITIVE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY AGRICULTURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY BIOCATALYSTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY RESEARCH & BIOTECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY COVALENT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY NON-COVALENT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ANTI-COAGULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ANTI-HYPERTENSIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ANTIBACTERIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ANTI-DEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY LARGE MOLECULE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY KINASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PHOSPHATASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY POLYMERASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL ENZYME INHIBITOR MARKET SIZE, BY PROTEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. ARGENTINA ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. BRAZIL ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. CANADA ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 105. CANADA ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. CANADA ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. CANADA ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. CANADA ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 117. MEXICO ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 118. MEXICO ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. MEXICO ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. MEXICO ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. MEXICO ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 131. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 135. UNITED STATES ENZYME INHIBITOR MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 156. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. AUSTRALIA ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 166. CHINA ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. CHINA ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. CHINA ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 169. CHINA ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 170. CHINA ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. CHINA ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 172. CHINA ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 173. CHINA ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. CHINA ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. CHINA ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 178. INDIA ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 179. INDIA ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. INDIA ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. INDIA ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 182. INDIA ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 183. INDIA ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. INDIA ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 185. INDIA ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. INDIA ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 187. INDIA ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. INDIA ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 191. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 192. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 195. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 196. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 197. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 198. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 199. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 200. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. INDONESIA ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 202. JAPAN ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. JAPAN ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 204. JAPAN ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 205. JAPAN ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. JAPAN ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 207. JAPAN ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 208. JAPAN ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 209. JAPAN ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 210. JAPAN ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 211. JAPAN ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 212. JAPAN ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 213. JAPAN ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. JAPAN ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 215. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 217. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 218. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 220. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 221. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 222. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 223. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 224. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 225. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 226. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. MALAYSIA ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 228. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 230. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 234. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 235. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 236. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 237. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 238. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 239. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. PHILIPPINES ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 241. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 243. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 244. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 246. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 247. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 248. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 249. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 250. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 251. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 252. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. SINGAPORE ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 254. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 256. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 257. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 258. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 259. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 260. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 261. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 262. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 263. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 264. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 265. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. SOUTH KOREA ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 267. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 269. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 270. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 272. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 273. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 274. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 275. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 276. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 277. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 278. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. TAIWAN ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 280. THAILAND ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. THAILAND ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 282. THAILAND ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 283. THAILAND ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 284. THAILAND ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 285. THAILAND ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 286. THAILAND ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 287. THAILAND ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 288. THAILAND ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 289. THAILAND ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 290. THAILAND ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 291. THAILAND ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. THAILAND ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 293. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 294. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 295. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 296. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 297. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 298. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 299. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 300. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 301. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 302. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 303. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 304. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. VIETNAM ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 315. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 316. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 317. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 318. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 319. EUROPE, MIDDLE EAST & AFRICA ENZYME INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 320. DENMARK ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. DENMARK ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 322. DENMARK ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 323. DENMARK ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 324. DENMARK ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 325. DENMARK ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 326. DENMARK ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 327. DENMARK ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 328. DENMARK ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 329. DENMARK ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 330. DENMARK ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 331. DENMARK ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 332. DENMARK ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 333. EGYPT ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 334. EGYPT ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 335. EGYPT ENZYME INHIBITOR MARKET SIZE, BY NON-COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 336. EGYPT ENZYME INHIBITOR MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 337. EGYPT ENZYME INHIBITOR MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 338. EGYPT ENZYME INHIBITOR MARKET SIZE, BY INHIBITION MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 339. EGYPT ENZYME INHIBITOR MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 340. EGYPT ENZYME INHIBITOR MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 341. EGYPT ENZYME INHIBITOR MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 342. EGYPT ENZYME INHIBITOR MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 343. EGYPT ENZYME INHIBITOR MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 344. EGYPT ENZYME INHIBITOR MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 345. EGYPT ENZYME INHIBITOR MARKET SIZE, BY ENZYME TARGET, 2018-2030 (USD MILLION)
  • TABLE 346. FINLAND ENZYME INHIBITOR MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 347. FINLAND ENZYME INHIBITOR MARKET SIZE, BY COMPETITIVE INHIBITORS, 2018-2030 (USD MILLION)

TABLE